Stocks and Investing
Stocks and Investing
Mon, November 15, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (AKRO) at Strong Buy with Decreased Target to $62 on, Nov 15th, 2021
Ed Arce of HC Wainwright & Co., Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Decreased Target from $64 to $62 on, Nov 15th, 2021.
Ed has made no other calls on AKRO in the last 4 months.
There is 1 other peer that has a rating on AKRO. Out of the 1 peers that are also analyzing AKRO, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Aspen Mori of "B of A Securities" Initiated at Strong Buy and Held Target at $40 on, Friday, September 10th, 2021
Contributing Sources